

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **The United Laboratories International Holdings Limited**

**聯邦制藥國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 3933)

### **VOLUNTARY ANNOUNCEMENT PROPOSED SHARE BUY-BACK UNDER GENERAL MANDATE**

This announcement is made by The United Laboratories International Holdings Limited (the “Company”) on a voluntary basis.

The board of directors of the Company (the “Board”) hereby announces that it intends to exercise its powers under the general mandate to buy back (the “Repurchase Mandate”) the shares of the Company (the “Shares”) granted by the shareholders of the Company (the “Shareholders”) at the annual general meeting of the Company held on 21 June 2022, to buy back the Shares of up to HK\$50 million in the open market at appropriate timing (the “Proposed Share Buy-Back”). The Company will subsequently cancel the bought Shares.

The Proposed Share Buy-Back will be financed by internal cash. The Board is confident with existing solid and healthy financial position of the Company and is of the view that the Proposed Share Buy-Back is in the interest of the Company and the Shareholders as a whole. The Proposed Share Buy-Back and subsequent cancellation of the bought Shares would enhance the value of the Shares and improve return to the Shareholders.

**Shareholders and potential investors of the Company should note that, the exercise of the Repurchase Mandate by the Board will be subject to market conditions and will be at the absolute discretion of the Board. There is no assurance of the timing, quantity or price of any share buy-back or whether or not the Company will make the buy-backs. Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.**

On behalf of the Board

**The United Laboratories International Holdings Limited**

**Tsoi Hoi Shan**

*Chairman*

Hong Kong, 22 September 2022

*As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.*